Mercedes Beatriz Fuertes

Mercedes Beatriz Fuertes

Auto-generated profile, based on publicly available information

Mercedes Beatriz Fuertes

Laboratorio de Fisiopatología de la Inmunidad Innata, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Immunity
Verified
Journal Article
Closed access
SWSeng-Ryong Woo
Seng-Ryong Woo
MFMercedes B. Fuertes
Mercedes B. Fuertes
LCLeticia Corrales
Leticia Corrales
SSStefani Spranger
Stefani Spranger
MFMichael J. Furdyna
Michael J. Furdyna
TGThomas F. Gajewski
Thomas F. Gajewski

19 September 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
MFMercedes B. Fuertes
Mercedes B. Fuertes
AKAalok K. Kacha
Aalok K. Kacha
JKJustin Kline
Justin Kline
SWSeng-Ryong Woo
Seng-Ryong Woo
DKDavid M. Kranz
David M. Kranz
TGThomas F. Gajewski
Thomas F. Gajewski
Despite lack of tumor control in many models, spontaneous T cell priming occurs frequently in response to a growing tumor. However, the innate immune mechanisms that promote natural antitumor T cell responses are undefined. In human metastatic melanoma, there was a correlation between a type I interferon (IFN) transcriptional profile and T cell markers in metastatic tumor tissue. In mice, IFN-β was produced by CD11c+ cells after tumor implantation, and tumor-induced T cell priming was defective in mice lacking IFN-α/βR or Stat1. IFN signaling was required in the hematopoietic compartment at the level of host antigen-presenting cells, and selectively for intratumoral accumulation of CD8α+ dendritic cells, which were demonstrated to be essential using Batf3−/− mice. Thus, host type I IFNs are critical for the innate immune recognition of a growing tumor through signaling on CD8α+ DCs.

1 February 2013 in Trends in Immunology
Verified
Journal Article
Closed access
MFMercedes B. Fuertes
Mercedes B. Fuertes
SWSeng-Ryong Woo
Seng-Ryong Woo
BBByron Burnett
Byron Burnett
YFYang-Xin Fu
Yang-Xin Fu
TGThomas F. Gajewski
Thomas F. Gajewski

1 April 2011 in Current Opinion in Immunology
Verified
Journal Article
Open access
TGThomas F Gajewski
Thomas F Gajewski
MFMercedes Fuertes
Mercedes Fuertes
RSRobbert Spaapen
Robbert Spaapen
YZYan Zheng
Yan Zheng
JKJustin Kline
Justin Kline
The molecular identification of tumor antigens initially catalyzed substantial enthusiasm for the development of tumor antigen-based vaccines for the treatment of cancer. However, numerous vaccine approaches in melanoma and other cancers have yielded a low rate of clinical response, despite frequent induction of specific T cells as detected in the peripheral blood. This observation has prompted several investigators to begin interrogating the tumor microenvironment for biologic correlates to tumor response versus resistance. Evidence is beginning to emerge suggesting that distinct subsets of tumors may exist that reflect distinct categories of immune escape. Lack of chemokine-mediated trafficking, poor innate immune cell activation, and the presence of specific immune suppressive mechanisms can be found to characterize subsets of tumors. A non-inflamed tumor phenotype may predict for resistance to cancer vaccines, suggesting a possible predictive biomarker and patient enrichment strategy. But in addition, characterization of these subsets may pave the way for catering therapeutic interventions toward the biologic features of the tumor in individual patients.

15 September 2007 in The Journal of Immunology
Verified
Journal Article
Closed access
MGMaría V Girart
María V Girart
MFMercedes B Fuertes
Mercedes B Fuertes
CDCarolina I Domaica
Carolina I Domaica
LRLucas E Rossi
Lucas E Rossi
NZNorberto Zwirner
Norberto Zwirner
NK cells express different TLRs, such as TLR3, TLR7, and TLR9, but little is known about their role in NK cell stimulation. In this study, we used specific agonists (poly(I:C), loxoribine, and synthetic oligonucleotides containing unmethylated CpG sequences to stimulate human NK cells without or with suboptimal doses of IL-12, IL-15, or IFN-α, and investigated the secretion of IFN-γ, cytotoxicity, and expression of the activating receptor NKG2D. Poly(I:C) and loxoribine, in conjunction with IL-12, but not IL-15, triggered secretion of IFN-γ. Inhibition of IFN-γ secretion by chloroquine suggested that internalization of the TLR agonists was necessary. Also, secretion of IFN-γ was dependent on MEK1/ERK, p38 MAPK, p70S6 kinase, and NF-κB, but not on calcineurin. IFN-α induced a similar effect, but promoted lesser IFN-γ secretion. However, cytotoxicity (51Cr release assays) against MHC class I-chain related A (MICA)− and MICA+ tumor targets remained unchanged, as well as the expression of the NKG2D receptor. Excitingly, IFN-γ secretion was significantly increased when NK cells were stimulated with poly(I:C) or loxoribine and IL-12, and NKG2D engagement was induced by coculture with MICA+ tumor cells in a PI3K-dependent manner. We conclude that resting NK cells secrete high levels of IFN-γ in response to agonists of TLR3 or TLR7 and IL-12, and this effect can be further enhanced by costimulation through NKG2D. Hence, integration of the signaling cascades that involve TLR3, TLR7, IL-12, and NKG2D emerges as a critical step to promote IFN-γ-dependent NK cell-mediated effector functions, which could be a strategy to promote Th1-biased immune responses in pathological situations such as cancer.

1 August 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
XIXimena L. Raffo Iraolagoitia
Ximena L. Raffo Iraolagoitia
RSRaul G. Spallanzani
Raul G. Spallanzani
NTNicolas Torres
Nicolas Torres
RARomina E Araya
Romina E Araya
AZAndrea Ziblat
Andrea Ziblat
MFMercedes B. Fuertes
Mercedes B. Fuertes
Despite the classical function of NK cells in the elimination of tumor and of virus-infected cells, evidence for a regulatory role for NK cells has been emerging in different models of autoimmunity, transplantation, and viral infections. However, this role has not been fully explored in the context of a growing tumor. In this article, we show that NK cells can limit spontaneous cross-priming of tumor Ag-specific CD8+ T cells, leading to reduced memory responses. After challenge with MC57 cells transduced to express the model Ag SIY (MC57.SIY), NK cell–depleted mice exhibited a significantly higher frequency of SIY-specific CD8+ T cells, with enhanced IFN-γ production and cytotoxic capability. Depletion of NK cells resulted in a CD8+ T cell population skewed toward an effector memory T phenotype that was associated with enhanced recall responses and delayed tumor growth after a secondary tumor challenge with B16.SIY cells. Dendritic cells (DCs) from NK cell–depleted tumor-bearing mice exhibited a more mature phenotype. Interestingly, tumor-infiltrating and tumor-draining lymph node NK cells displayed an upregulated expression of the inhibitory molecule programmed death ligand 1 that, through interaction with programmed death-1 expressed on DCs, limited DC activation, explaining their reduced ability to induce tumor-specific CD8+ T cell priming. Our results suggest that NK cells can, in certain contexts, have an inhibitory effect on antitumor immunity, a finding with implications for immunotherapy in the clinic.